Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia
/in Chronic Leukemia, International Publications /von 2008-04-21 / J. Leukoc. Biol. 2008 Jul;84(1):319-25Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model
/in Glioblastoma, International Publications /von 2008-04-15 / Int. J. Cancer 2008 Apr;122(8):1794-802Cell- and peptide-based immunotherapeutic approaches for glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2008-04-09 / Trends Mol Med 2008 May;14(5):228-35Reengineering dendritic cell-based anti-cancer vaccines
/in Breast Cancer, International Publications /von 2008-04-01 / Immunol. Rev. 2008 Apr;222:256-76The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
/in HIV/AIDS, International Publications /von 2008-04-01 / J. Clin. Invest. 2008 Apr;118(4):1427-36An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89Strategies and challenges in eliciting immunity to melanoma
/in International Publications, Malignant Melanoma /von 2008-04-01 / Immunol. Rev. 2008 Apr;222:28-42Cancer vaccines for established cancer: how to make them better?
/in International Publications, Malignant Melanoma /von 2008-04-01 / Immunol. Rev. 2008 Apr;222:242-55Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells
/in International Publications, Malignant Melanoma /von 2008-04-01 / Cancer Biother. Radiopharm. 2008 Apr;23(2):214-21
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution